Results 21 to 30 of about 28,157 (212)
Safety and BNT162b2 mRNA COVID-19 vaccination.
Acta bio-medica : Atenei Parmensis, 2021 n/a.
Joob, Beuy, Wiwanitkit, Viroj
openaire +2 more sources
Human Vaccines & Immunotherapeutics, 2023 The mRNA-based BNT162b2 and inactivated whole-virus CoronaVac are two widely used COVID-19 vaccines that confer immune protection to healthy individuals. However, hesitancy toward COVID-19 vaccination appeared to be common for patients with neuromuscular
Michael Kwan Leung Yu +9 more
doaj +1 more source
COVID-19 vaccine in the Kingdom of Saudi Arabia: A true operation warp speed
Journal of Nature and Science of Medicine, 2021 As of January 2021, 1 year has passed since the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was first discovered, which is the cause of the coronavirus disease-2019 (COVID-19) pandemic that has infected almost 100 million people ...
Mazin Barry, Ahmed S BaHammam
doaj +1 more source
Extended interval BNT162b2 vaccination enhances peak antibody generation [PDF]
npj Vaccines, 2022 Abstract The BNT162b2 vaccine is highly effective against COVID-19 infection and was delivered with a 3-week time interval in registration studies 1 . However, many countries extended this interval to accelerate population coverage with a single vaccine.
Helen Parry +9 more
openaire +3 more sources
BNT162b2 mRNA COVID-19 Vaccine: First Approval [PDF]
Drugs, 2021 BNT162b2 (Comirnaty®; BioNTech and Pfizer) is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine for the prevention of the novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
openaire +2 more sources
Myopericarditis following both BNT162b2 and NVX-CoV2373
Allergy, Asthma & Clinical Immunology, 2022 Abstract Background Myopericarditis is a well reported complication associated with SARS-Cov-2 (COVID-19) infection and vaccinations; particularly with mRNA vaccines (BNT162b2 and mRNA-1273), and in the young male population.
Saima Ahmad +3 more
openaire +3 more sources
Why COVID vaccines for young children (5–11 years) are not essential at this moment in time?
Journal of Pharmaceutical Policy and Practice, 2022 The Joint Committee on Vaccination and Immunisation (JCVI) in UK has recently advised that COVID vaccines in 5–11-year-old children is non-essential. This has created an outrage among some healthcare professionals who believed a mandatory vaccination ...
Hamid A. Merchant
doaj +1 more source
Concomitant Peripheral and Pulmonary Arterial Thromboembolism 35 Days After SARS-CoV-2 mRNA Vaccine
Cam & Sakura Medical Journal, 2023 Although thromboembolism after ChAdOx1 vaccine has been extensively reported, this association was rarely reported after vaccination with BNT162b2. We present the case of an otherwise healthy patient who developed concomitant acute limb ischemia and ...
Ahmet Can Topçu +3 more
doaj +1 more source
Acute myocarditis following administration of BNT162b2 vaccine
IDCases, 2021 The wide use of vaccines was linked with rare but serious complications in adults, causing a global concern. Here, we describe a young male patient, who presented with acute myocarditis, three days after the second dose of BNT162b2 vaccine.
Mhd Baraa Habib +4 more
openaire +3 more sources
Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era
Expert Review of Vaccines, 2023 Introduction The Omicron BA.1 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and subsequent sub-lineages exhibit partial escape from neutralizing antibodies elicited by vaccines containing or encoding wild-type spike protein.
Shanti Pather +3 more
doaj +1 more source